Associated Papers
Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease.
Marie V et al.
Journal of Biomolecular Structure & Dynamics, 2022
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Blanch-Lombarte O et al.
The Journal of Antimicrobial Chemotherapy, 2020
Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.
Stekler JD et al.
Plos Medicine, 2018
29584723 (PubMed )
Supplement: pmed.1002537.s002.doc
Epistasis as a determinant of the HIV-1 protease's robustness to mutation.
Capel E et al.
Plos One, 2014
Potential elucidation of a novel CTL epitope in HIV-1 protease by the protease inhibitor resistance mutation L90M.
Smidt W
Plos One, 2013
Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.
Koh Y et al.
Journal of Virology, 2011
Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Margot NA et al.
Antimicrobial Agents and Chemotherapy, 2010
In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1.
Kitchen CM et al.
The Open Medical Informatics Journal, 2010
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
Malet I et al.
The Journal of Infection, 2007
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S et al.
Antimicrobial Agents and Chemotherapy, 2005
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D et al.
Antiviral Therapy, 2004
Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions.
Cabana M et al.
Virology, 2002
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.
Sugiura W et al.
Antimicrobial Agents and Chemotherapy, 2002
Transmission of antiretroviral-drug-resistant HIV-1 variants.
Yerly S et al.
Lancet (london, England), 1999
Select a paper to view details